- Home
- VMD vs ATAI Comparison
VMD vs ATAI Comparison
Compare VMD & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMD
- ATAI
- Stock Information
- Founded
- VMD 2006
- ATAI 2018
- Country
- VMD United States
- ATAI Germany
- Employees
- VMD N/A
- ATAI N/A
- Industry
- VMD
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- VMD
- ATAI Health Care
- Exchange
- VMD Nasdaq
- ATAI Nasdaq
- Market Cap
- VMD 280.4M
- ATAI 444.7M
- IPO Year
- VMD N/A
- ATAI 2021
- Fundamental
- Price
- VMD $6.52
- ATAI $4.61
- Analyst Decision
- VMD
- ATAI Strong Buy
- Analyst Count
- VMD 0
- ATAI 3
- Target Price
- VMD N/A
- ATAI $13.33
- AVG Volume (30 Days)
- VMD 216.1K
- ATAI 4.7M
- Earning Date
- VMD 11-05-2025
- ATAI 11-12-2025
- Dividend Yield
- VMD N/A
- ATAI N/A
- EPS Growth
- VMD 47.14
- ATAI N/A
- EPS
- VMD 0.34
- ATAI N/A
- Revenue
- VMD $240,884,000.00
- ATAI $2,309,000.00
- Revenue This Year
- VMD $19.22
- ATAI $712.99
- Revenue Next Year
- VMD $17.51
- ATAI N/A
- P/E Ratio
- VMD $19.39
- ATAI N/A
- Revenue Growth
- VMD 17.11
- ATAI 510.85
- 52 Week Low
- VMD $5.93
- ATAI $1.03
- 52 Week High
- VMD $9.81
- ATAI $5.34
- Technical
- Relative Strength Index (RSI)
- VMD 41.19
- ATAI 57.88
- Support Level
- VMD $6.55
- ATAI $4.50
- Resistance Level
- VMD $6.94
- ATAI $4.75
- Average True Range (ATR)
- VMD 0.21
- ATAI 0.28
- MACD
- VMD -0.05
- ATAI -0.04
- Stochastic Oscillator
- VMD 1.05
- ATAI 50.33
About VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.